New Color On PCSK9 Inhibitors Previews Commercial Competition
This article was originally published in The Pink Sheet Daily
The sponsors of the PCSK9 inhibitor class are getting lots of data boxes ticked off with the results presented at the American College of Cardiology, but it’s still largely a waiting game as investors, practitioners and patients wait for regulatory submissions and outcomes trials. New details on doses and devices preview commercial battle between Amgen’s evolocumab and Sanofi/Regeneron’s alirocumab.
You may also be interested in...
All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.
The US FDA granted an accelerated approval to Sarepta’s Elevidys, the first gene therapy to be approved for some children with Duchenne muscular dystrophy.
The deadline is approaching for submissions to the 2023 Citeline Awards; gain recognition for your clinical research team, real world evidence project, diversity and inclusion efforts, and more.